JP2020531511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531511A5 JP2020531511A5 JP2020511176A JP2020511176A JP2020531511A5 JP 2020531511 A5 JP2020531511 A5 JP 2020531511A5 JP 2020511176 A JP2020511176 A JP 2020511176A JP 2020511176 A JP2020511176 A JP 2020511176A JP 2020531511 A5 JP2020531511 A5 JP 2020531511A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- patient
- eye
- micrograms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000003889 eye drop Substances 0.000 claims 14
- 229940126062 Compound A Drugs 0.000 claims 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 8
- 229940012356 eye drops Drugs 0.000 claims 8
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 6
- 230000004489 tear production Effects 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549872P | 2017-08-24 | 2017-08-24 | |
| US62/549,872 | 2017-08-24 | ||
| PCT/US2018/048025 WO2019040919A1 (en) | 2017-08-24 | 2018-08-24 | OCULAR PHARMACEUTICAL COMPOSITIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531511A JP2020531511A (ja) | 2020-11-05 |
| JP2020531511A5 true JP2020531511A5 (enExample) | 2021-09-30 |
Family
ID=65439930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511176A Pending JP2020531511A (ja) | 2017-08-24 | 2018-08-24 | 眼球用医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11839616B2 (enExample) |
| EP (1) | EP3672598A4 (enExample) |
| JP (1) | JP2020531511A (enExample) |
| KR (1) | KR20200044873A (enExample) |
| CN (1) | CN111629730A (enExample) |
| AU (1) | AU2018321926B2 (enExample) |
| CA (1) | CA3073718A1 (enExample) |
| WO (1) | WO2019040919A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2909316T3 (es) | 2015-12-24 | 2022-05-06 | Univ California | Reguladores de CFTR y métodos de uso de los mismos |
| KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
| US11957413B2 (en) * | 2019-08-06 | 2024-04-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Solitary wave-based trans-lid tonometer |
| TWI845795B (zh) * | 2019-12-05 | 2024-06-21 | 美商汎達製藥公司 | 眼用醫藥組合物 |
| US20220071549A1 (en) * | 2020-09-08 | 2022-03-10 | The Regents Of The University Of California | Apparatus, systems and methods of use for ocular surface potential difference measurement |
| CN116507336B (zh) * | 2020-09-10 | 2026-01-02 | Vanda制药公司 | 治疗pde iv介导的疾病或病症的方法 |
| AU2025224045A1 (en) * | 2024-02-22 | 2026-08-06 | Vanda Pharmaceuticals, Inc. | Treatment of dry eye disease |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0008864A1 (en) | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| JPS62126178A (ja) | 1985-11-26 | 1987-06-08 | Mitsubishi Petrochem Co Ltd | 新規トリアジン誘導体及びこれを含む除草剤 |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| AU5433594A (en) | 1992-11-19 | 1994-06-08 | Dainippon Pharmaceutical Co. Ltd. | 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound |
| IL137128A0 (en) | 1998-01-30 | 2001-07-24 | R Tech Ueno Ltd | Ophthalmic compositions containing tetrahydroquinazoline derivatives |
| EP0945447A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
| BR9815785A (pt) | 1998-03-31 | 2000-12-05 | Warner Lambert Co | Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina |
| CA2396693A1 (en) | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
| PL369600A1 (en) | 2001-09-21 | 2005-05-02 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| US7163943B2 (en) | 2001-09-21 | 2007-01-16 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| WO2004031184A1 (en) | 2002-10-01 | 2004-04-15 | Johnson & Johnson Pharmaceutical Research & Development, Inc. | 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors |
| WO2005009980A1 (en) | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
| BRPI0507278A (pt) | 2004-01-30 | 2007-06-26 | Vertex Pharma | moduladores dos transportadores do cassete de ligação ao atp |
| US7335770B2 (en) | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
| DE102004023332A1 (de) | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| WO2007095812A1 (en) | 2006-02-27 | 2007-08-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof |
| US8080563B2 (en) | 2006-07-07 | 2011-12-20 | Kalypsys | Bicyclic heteroaryl inhibitors of PDE4 |
| US8263607B2 (en) | 2007-05-22 | 2012-09-11 | Astellas Pharma Inc. | 1-substituted tetrahydroisoquinoline compound |
| US20090105240A1 (en) | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
| WO2009091388A2 (en) | 2007-12-21 | 2009-07-23 | Progenics Pharmaceuticals, Inc. | Triazines and related compounds having antiviral activity, compositions and methods thereof |
| ES2548583T3 (es) | 2008-03-05 | 2015-10-19 | Merck Patent Gmbh | Derivados de quinoxalinona como estimuladores de la secreción de insulina, métodos para su obtención y su uso para el tratamiento de la diabetes |
| US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2010073011A2 (en) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| SI3330255T1 (sl) | 2009-03-20 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi |
| FR2958645B1 (fr) | 2010-04-09 | 2012-08-31 | Commissariat Energie Atomique | Hemi-anticorps a auto-assemblage |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| TWI450891B (zh) | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| CA2895656A1 (en) | 2012-12-19 | 2014-06-26 | Novartis Ag | Tricyclic compounds as cftr inhibitors |
| AU2014304562B8 (en) | 2013-08-08 | 2018-07-05 | Galapagos Nv | Thieno[2,3-c]pyrans as CFTR modulators |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| US10354851B2 (en) | 2015-09-11 | 2019-07-16 | Iontof Technologies Gmbh | Secondary ion mass spectrometer and secondary ion mass spectrometric method |
| US10035962B2 (en) * | 2015-12-21 | 2018-07-31 | Exxonmobil Research And Engineering Company | Trim dewaxing of distillate fuel |
| ES2909316T3 (es) | 2015-12-24 | 2022-05-06 | Univ California | Reguladores de CFTR y métodos de uso de los mismos |
| ES2956820T3 (es) | 2015-12-24 | 2023-12-28 | Respivert Ltd | Compuestos de indolinonas y su uso en el tratamiento de enfermedades fibróticas |
| RU2730855C2 (ru) | 2015-12-24 | 2020-08-26 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа | Кфтр регуляторы и способы их применения |
| RU2742934C2 (ru) | 2015-12-24 | 2021-02-11 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа | Кфтр регуляторы и способы их применения |
| KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
-
2018
- 2018-08-24 KR KR1020207008360A patent/KR20200044873A/ko not_active Ceased
- 2018-08-24 AU AU2018321926A patent/AU2018321926B2/en active Active
- 2018-08-24 US US16/641,621 patent/US11839616B2/en active Active
- 2018-08-24 WO PCT/US2018/048025 patent/WO2019040919A1/en not_active Ceased
- 2018-08-24 CN CN201880069116.7A patent/CN111629730A/zh active Pending
- 2018-08-24 EP EP18849250.8A patent/EP3672598A4/en active Pending
- 2018-08-24 JP JP2020511176A patent/JP2020531511A/ja active Pending
- 2018-08-24 CA CA3073718A patent/CA3073718A1/en active Pending
-
2023
- 2023-10-30 US US18/497,962 patent/US20240156828A1/en not_active Abandoned
-
2025
- 2025-08-11 US US19/296,874 patent/US20250367207A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7863279B2 (ja) | 眼科用組成物 | |
| Moiseev et al. | Penetration enhancers in ocular drug delivery | |
| JP7012075B2 (ja) | 眼瞼炎の治療に使用するための医薬組成物 | |
| CN105307498B (zh) | 用于治疗眼病的组合物、制剂和方法 | |
| WO2017158366A3 (en) | Ophthalmic delivery device and ophthalmic drug compositions | |
| NZ785712A (en) | Neuroactive steroids, compositions, and uses thereof | |
| RU2017129247A (ru) | Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний | |
| JP2009530234A5 (enExample) | ||
| JP2011516477A5 (enExample) | ||
| TN2010000251A1 (fr) | N-acetyl-dl-leucine medicament neuro et retino protecteur | |
| JP2019529541A5 (enExample) | ||
| JP2017520527A5 (enExample) | ||
| JP2013534527A5 (enExample) | ||
| EA201300314A1 (ru) | Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство | |
| JP2009501726A (ja) | 眼科学的活性剤の製剤とその投与の方法 | |
| Cegielska et al. | Targeted drug delivery systems for the treatment of glaucoma: Most advanced systems review | |
| WO2016208961A1 (ko) | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 | |
| JP6871400B2 (ja) | 眼表面疾患の治療のための製剤および関連方法 | |
| US9320645B2 (en) | Approach to administering ocular medication | |
| JP2018500546A5 (enExample) | ||
| JP2008540528A5 (enExample) | ||
| EP4225279A1 (en) | Drug containing dissolvable ocular inserts and method of using same | |
| JP2018519299A (ja) | 組成物および治療方法 | |
| JP2019502719A5 (enExample) | ||
| CN103720524A (zh) | 一种制作灵长类动物干性年龄相关性黄斑变性疾病模型的方法 |